Engineering IL-2 for immunotherapy of autoimmunity and cancer
Engineering IL-2 for immunotherapy of autoimmunity and cancer
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Preclinical studies of the T cell growth factor activity of IL-2 resulted in this cytokine becoming the first immunotherapy to be approved nearly 30 years ago by the US Food and Drug Administration for the treatment of cancer. Since then, we have learnt the important role of IL-2 in regulating tolerance through regulatory T cells (T
reg
cells...
Alternative Titles
Full title
Engineering IL-2 for immunotherapy of autoimmunity and cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2633854607
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2633854607
Other Identifiers
ISSN
1474-1733
E-ISSN
1474-1741
DOI
10.1038/s41577-022-00680-w
